• Nenhum resultado encontrado

Rev. Bras. Hematol. Hemoter. vol.30 suppl.2

N/A
N/A
Protected

Academic year: 2018

Share "Rev. Bras. Hematol. Hemoter. vol.30 suppl.2"

Copied!
6
0
0

Texto

Loading

Referências

Documentos relacionados

ATRA treatment induces increase in the expression of adhesion molecules such as CD11b, CD18 and ICAM-1, which increase the adhesion of myeloid to endothelial cells, thus

Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA

Minimal residual disease (MRD) was monitored in 80 patients with acute lymphoid (ALL, n=44) or myeloid (AML, n=36) leukemia, undergoing allogeneic haemopoietic stem

Adult T-lymphoblastic lymphoma is rare and has a poor prognosis. In the 80s, following the introduction of sequential, intensified chemotherapy, complete remissions in the order

A GITIL prospective randomized multicenter phase III study of high dose sequential chemotherapy with rituximab (R- HDS and autologous transplantation (ASCT) of peripheral blood

In this review, we present 1) scientific basis for the use of high dose immunosuppression followed by autologous peripheral blood hematopoietic stem cell transplantation for

São editores con- vidados o Professor Ricardo Pasquini, da Universidade Fe- deral do Paraná (UFP, PR), e o Professor Cármino Antonio de Souza, da Universidade Estadual de

A nova era no tratamento da LMC promoveu o desenvolvi- mento de recursos para o monitoramento de maior eficiên- cia e sensibilidade da doença residual, fundamental para